Loading
The North American version of the same question, with the same answer: cetuximab after surgery adds toxicity and no benefit.
N0147 randomised patients with resected stage III colon cancer to mFOLFOX6 with or without cetuximab. Three-year disease-free survival was 74.6 percent with chemotherapy alone against 71.5 percent with cetuximab added in KRAS wild-type disease (hazard ratio 1.21, 95% CI 0.98 to 1.49, p=0.08), and 67.1 against 65.0 percent in KRAS-mutant disease. Grade 3 or higher adverse events rose from 52.3 to 72.5 percent. No subgroup benefited. The trial also contributed the mismatch-repair and BRAF cohorts that later defined which stage III tumours are immunologically distinct, the biology that ATOMIC acted on thirteen years later.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Colorectal cancer: the failed and stopped programmes, and why, Oxaliplatin, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin).
Shares Oxaliplatin, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), EGFR.
Shares Alliance for Clinical Trials in Oncology, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), EGFR.
Shares PETACC-3, Oxaliplatin, FOLFOX (5-FU, leucovorin, oxaliplatin), Colon cancer (adenocarcinoma of the colon).
Shares Oxaliplatin, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), EGFR.
Shares Oxaliplatin, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), EGFR.
Shares Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon).
Shares Alliance for Clinical Trials in Oncology, Irinotecan (and liposomal irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colon cancer (adenocarcinoma of the colon).